Novartis AG ADR (NVS) carries a ŷRobot AI score of 70 out of 100. The model's fair value estimate is $164.16, 12.7% above the last close of $145.71. The chart signal reads Bullish.
| Metric | NVS |
|---|---|
| AI score | 70 / 100 |
| Chart signal | Bullish |
| Fair value estimate | $164.16 |
| Upside to fair value | 12.7% |
| Previous close | $145.71 |
| P/E | 23.27 |
| Price / sales | 5.10 |
| Market cap | $279.18B |
| EPS | 6.61 |
| Revenue growth | 8.0% |
| 1-year price change | 12.5% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, AstraZeneca PLC.
As of Sep 29, 2026, ŷRobot's fair-value model estimates Novartis AG ADR (NVS) at $164.16 against a last close of $145.71, implying 12.7% upside to the model's estimate.
The chart-signal model classifies NVS as Bullish as of Sep 29, 2026, with a signal score of 0.16 on a -1 to 1 scale.
NVS scores 70 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 29, 2026.
NVS trades at 23.3 times earnings and 5.1 times sales as of Sep 29, 2026.
ŷRobot's seasonal forecast curve for NVS reads -1.5% at 30 days, +4.3% at 90 days, and +12.5% at one year as of Sep 29, 2026. Seasonal tendencies are historical patterns, not predictions.
Novartis AG ADR's revenue growth is +8.0% and free-cash-flow growth is +0.5% on the latest reported figures.
NVS chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.